ARTICLE | Company News
Elan drug delivery, neurology, autoimmune news
September 13, 2010 7:00 AM UTC
Elan started the review after a proposed $1 billion investment from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) was reduced to $885 million due to a 2009 ruling in the U.S. District Court for t...